Intellia Therapeutics (NASDAQ:NTLA) Shares Climb 4.4% – Should You Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) was up 4.4% on Monday. The company traded as high as $10.46 and last traded at $10.1250. 1,057,048 shares were traded during trading, a decline of 79% from the average session volume of 5,111,479 shares. The stock had previously closed at $9.70.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NTLA shares. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Wedbush boosted their price target on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Wall Street Zen lowered Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $21.44.

View Our Latest Stock Analysis on NTLA

Intellia Therapeutics Stock Performance

The firm’s 50 day moving average price is $11.92 and its 200-day moving average price is $12.96. The firm has a market capitalization of $1.40 billion, a PE ratio of -2.98 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Intellia Therapeutics had a negative net margin of 805.75% and a negative return on equity of 64.74%. The business had revenue of $7.16 million for the quarter, compared to analyst estimates of $9.74 million. During the same quarter last year, the business earned ($0.92) earnings per share. Intellia Therapeutics’s revenue was down 47.8% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares of the company’s stock, valued at approximately $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Cetera Investment Advisers lifted its position in shares of Intellia Therapeutics by 13.1% during the 3rd quarter. Cetera Investment Advisers now owns 75,679 shares of the company’s stock valued at $913,000 after buying an additional 8,737 shares in the last quarter. Entropy Technologies LP acquired a new stake in Intellia Therapeutics in the 3rd quarter valued at $1,448,000. Pathstone Holdings LLC grew its stake in Intellia Therapeutics by 6.9% in the 3rd quarter. Pathstone Holdings LLC now owns 41,468 shares of the company’s stock valued at $500,000 after acquiring an additional 2,686 shares during the period. Steward Partners Investment Advisory LLC grew its stake in Intellia Therapeutics by 225.7% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,088 shares of the company’s stock valued at $25,000 after acquiring an additional 1,447 shares during the period. Finally, Insigneo Advisory Services LLC increased its holdings in Intellia Therapeutics by 175.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 33,000 shares of the company’s stock worth $398,000 after acquiring an additional 21,000 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

See Also

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.